echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > GUT: Evaluation of the clinical management effectiveness of Helicobacter pyridobacteria in European countries since 2013.

    GUT: Evaluation of the clinical management effectiveness of Helicobacter pyridobacteria in European countries since 2013.

    • Last Update: 2020-10-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    At present, the best method of clinical management of Helicobacterrobacteria is not clear.
    recently conducted an audit of clinical treatment data for Helicobacter pyridobacteria in Europe since 2013 to ensure that clinical practice meets the best standards of care.
    Data collection for this study, which began in 2013, aims to assess the results of clinical management of Helicobacter pyridosis in Europe, including demographics, previous eradication attempts, treatment options, adverse events and results.
    study data from 30,394 patients in 27 European countries, 21,533 (78%) received first-line experience of Helicobacter pyridobacteria treatment.
    statistics found that 23% of patients were resistant to kramycin, 32% to methazole and 13% to both.
    amoxilin and kramycin were the most common (39 per cent) treatments, with 81.5 per cent of patients achieving treatment eradication.
    more than 90% of patients can be eradicated only after receiving a combination or companion therapy.
    longer treatment time, high doses of stomach acid inhibitors and higher compliance were associated with higher eradication rates.
    time trend analysis shows regional dependence changes in prescriptions in countries, including the abandonment of triple therapy, the use of larger doses of stomach acid inhibitors and longer treatment times, which are associated with increased overall eradication effectiveness (84-90 per cent).
    study concluded that only four combination therapies that last at least 10 days in European countries can achieve more than 90% helicobacter pyridobacteria eradication rate, indicating that the European Helicobacter pyridobacteria clinical treatment has a greater heterogeneity, the best clinical treatment guidelines have not been strictly adhered to.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.